Fig. 1. Tumor growth patterns of therapeutic vaccination of CT26-4-1BBL.
CT26-WT (wildtype) was subcutaneously administrated (2×105 cell/100 μL PBS) into the left flank of each mouse. Three days later, doxorubicin-treated CT26-beta-gal and CT26-4-1BBL (2×105 cell/100 μL) were subcutaneously administrated into the right flank. Tumor size was measured every third day. Single vaccination: (A) Tumor growth patterns of individual mice in each group, (B) Average tumor volume of each group. Triple vaccination: (C) Tumor growth patterns of individual mice in each group, (D) Average tumor volume of each group. (E) Comparison of single vaccination and triple vaccination. *: P < 0.05.
© 2022 Biomed Sci Letters
